The administration of l-dopa suppresses prolactin (PRL) secretion in normal subjects and in patients with hyperprolactinemia, although it is not known whether this effect, which requires the conversion of dopa to dopamine, is mediated peripherally or through the central nervous system. To distinguish between these effects, 10 normal subjects (6 male, 4 female) and 8 patients with hyperprolactinemia associated with pituitary tumors were given l-dopa, 0.5 g alone, or 0.1 g after a 24-h pretreatment with carbidopa, 50 mg every 6 h, which produces peripheral dopa decarboxylase inhibition. Similar degrees of PRL suppression were observed in normal subjects (basal plasma PRL 13±2 ng/ml) after l-dopa alone (48±4%) and after l-dopa plus carbidopa (58±6%). In patients with pituitary tumors and elevated plasma PRL (73±14 ng/ml), l-dopa alone led to PRL suppression comparable with that in normal subjects (47±6%). However, l-dopa plus carbidopa resulted in only minimal suppression of plasma PRL (19±4%) which was significantly less than after l-dopa alone (P < 0.001). Urinary homovanillic acid excretion, which reflected peripheral dopa decarboxylation was similar in controls and tumor patients after l-dopa both alone and after carbidopa pretreatment. Comparable suppression of PRL levels in response to a dopamine infusion (4 μg/kg per min for 3 h) was observed in controls and tumor patients. The results indicate that although peripheral conversion of exogenous dopa to dopamine can suppress PRL secretion, in normals, the central nervous system conversion of dopa to dopamine in the presence of peripheral dopa decarboxylase inhibition is sufficient to account for its PRL-suppressive effects. In contrast, patients with tumors, while retaining peripheral dopaminergic inhibitory effects on PRL secretion, exhibit a marked reduction of central dopaminergic inhibition of PRL secretion.
Stuart A. Fine, Lawrence A. Frohman
Title and authors | Publication | Year |
---|---|---|
Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology
S Fanti, G Gnanasegaran, I Carrió |
2021 | |
The ancient Chinese formula Longdan Xiegan Tang improves antipsychotic-induced hyperprolactinemia by repairing the hypothalamic and pituitary TGF-β1 signaling in rats
L Ren, W Liu, C Wang, Y Yang, X Huang, C Wang, Y Li |
Journal of Ethnopharmacology | 2020 |
18F-FDOPA Uptake Reflects the Efficacy of Dopamine Agonists Treatment in Pituitary Prolactinoma:
C Heimburger, C Bund, P Addeo, B Goichot, A Imperiale |
Clinical Nuclear Medicine | 2018 |
Paeoniflorin and liquiritin, two major constituents in Chinese herbal formulas used to treat hyperprolactinemia-associated disorders, inhibits prolactin secretion in prolactinoma cells by different mechanisms
Y Wei, L La, L Wang, R Batey, C Wang, Y Li |
Journal of Ethnopharmacology | 2017 |
The renin-angiotensin-aldosterone axis in patients with tumoral hyperprolactinemia
P Mediskou, MP Yavropoulou, K Kotsa, X Tsekmekidou, A Psarakou-Gotzamani, A Papazisi, A Chlorou, JG Yovos |
Clinical Endocrinology | 2011 |
Prolactin
MP Gillam, ME Molitch |
The Pituitary | 2011 |
Yen & Jaffe's Reproductive Endocrinology
RA Lobo |
Yen & Jaffe's Reproductive Endocrinology | 2009 |
Yen & Jaffe's Reproductive Endocrinology
SF Thung, ER Norwitz |
Yen & Jaffe's Reproductive Endocrinology | 2009 |
Diagnosis and Management of Pituitary Disorders
B Swearingen, BM Biller |
2008 | |
Persistence of hyperprolactinemia after treatment of primary hypothyroidism and withdrawal of long term use of estrogen: are the tuberoinfundibular dopaminergic neurons permanently lesioned?
LA Casulari, F Celotti, LA Naves, L Domingues, C Papadia |
Arquivos brasileiros de endocrinologia e metabologia | 2005 |
Prolactinomas: Aspectos neurocirúrgicos
OI Tella, MA Herculano, R Delcello, PH Aguiar |
Arquivos de Neuro-Psiquiatria | 2002 |
MEDICAL TREATMENT OF PROLACTINOMAS
ME Molitch |
Endocrinology and metabolism clinics of North America | 1999 |
Tamoxifen Inhibits GH3 Cell Growth in Culture via Enhancement of Apoptosis
SY Lee, BT Ahn, SH Baik, BL Lee |
Neurosurgery | 1998 |
Current Techniques in Neurosurgery
M Salcman |
1998 | |
Advances and Technical Standards in Neurosurgery
F Cohadon, VV Dolenc, JL Antunes, H Nornes, JD Pickard, HJ Reulen, AJ Strong, N de Tribolet, CA Tulleken |
Advances and technical standards in neurosurgery | 1997 |
Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinaemia
F Larrea, JL Sandoval, E Salinas, VA Franco-Rodriguez, I Méndez, A Ulloa-Aguirre |
Clinical Endocrinology | 1995 |
Dopamine, the dopamine D2 receptor and pituitary tumours
DF Wood, JM Johnston, DG Johnston |
Clinical Endocrinology | 1991 |
LONG-TERM FOLLOW-UP OF‘CURED’PROLACTINOMA PATIENTS AFTER SUCCESSFUL ADENOMECTOMY
E Ciccarelli, E Ghigo, C Miola, G Gandini, EE Muller, F Camanni |
Clinical Endocrinology | 1990 |
Defective natural killer cell activity in puerperal hyperprolactinemia
I Nicoletti, R Gerli, S Orlandi, G Migliorati, P Rambotti, C Riccardi |
Journal of Reproductive Immunology | 1989 |
Hyperprolactinemia: neuroendocrine and diagnostic aspects
F Camanni, E Ciccarelli, E Ghigo, EE Müller |
Journal of Endocrinological Investigation | 1989 |
Effect of neuroleptic withdrawal on plasma prolactin: A possible marker of receptor adaptation
B Kirkpatrick, RW Buchanan, K Maeda, WT Carpenter, D Jauch, CA Tamminga |
Biological Psychiatry | 1989 |
Suprasellar craniopharyngioma associated with hyperprolactinemia, pituitary lactotroph hyperplasia, and microprolactinoma
MD Cusimano, K Kovacs, JM Bilbao, WS Tucker, W Singer |
Journal of Neurosurgery | 1988 |
Therapeutic Applications of Bromocriptine in Endocrine and Neurological Diseases:
KY Ho, MO Thorner |
Drugs | 1988 |
Phenotypic and functional abnormalities of T lymphocytes in pathological hyperprolactinemia
R Gerli, C Riccardi, I Nicoletti, S Orlandi, C Cernetti, F Spinozzi, P Rambotti |
Journal of Clinical Immunology | 1987 |
Pathogenesis of Pituitary Tumors
ME Molitch |
Endocrinology and metabolism clinics of North America | 1987 |
The Pituitary Gland
CR Kannan |
1987 | |
Current Concepts and Treatment of Hyperprolactinemia
DF Archer |
Obstetrics and Gynecology Clinics of North America | 1987 |
THE PREOPERATIVE AND POSTOPERATIVE INVESTIGATION OF TSH AND PROLACTIN RELEASE IN THE MANAGEMENT OF PATIENTS WITH HYPERPROLACTINAEMIA DUE TO PROLACTINOMAS AND NONFUNCTIONAL PITUITARY TUMOURS: RELATIONSHIP TO ADENOMA SIZE AT SURGERY
MF Scanlon, JR Peters, J Salvador, SH Richards, R John, S Howell, ED Williams, JP Thomas, R Hall |
Clinical Endocrinology | 1986 |
Reduced number of natural killer cells in patients with pathological hyperprolactinemia
R Gerli, P Rambotti, I Nicoletti, S Orlandi, G Migliorati, C Riccardi |
Clinical & Experimental Immunology | 1986 |
FOLLOW-UP OF PROLACTIN LEVELS IN LONG-TERM OESTROGEN-TREATED MALE-TO-FEMALE TRANSSEXUALS WITH REGARD TO PROLACTINOMA INDUCTION
LJ Gooren, W Harmsen-Louman, H Kessel |
Clinical Endocrinology | 1985 |
LONG-TERM BROMOCRIPTINE THERAPY MAY RESTORE THE INHIBITORY CONTROL OF PROLACTIN RELEASE IN SOME PATIENTS WITH PATHOLOGICAL HYPERPROLACTINEMIA
KY Ho, GA Smythe, PJ Compton, L Lazarus |
Australian and New Zealand Journal of Medicine | 1985 |
Decreased tuberoinfundibular and pituitary dopamine and dihydroxyphenylacetic acid concentrations in rats with estrogen-induced pituitary tumors
TD Paolo, M Daigle, N Barden |
Neuroscience Letters | 1985 |
Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients
LD Marinis, A Mancini, S Minnielli, R Masala, C Anile, G Maira, A Barbarino |
Metabolism | 1985 |
Prolactin and growth hormone responses to dermorphin in patients with prolactin-secreting pituitary adenoma
EC Uberti, G Trasforini, S Salvadori, A Margutti, C Rotola, M Bianconi, V Teodori, R Tomatis, R Pansini |
Metabolism | 1985 |
Physiologic concentrations of dopamine fail to suppress prolactin secretion in patients with idiopathic hyperprolactinemia or prolactinomas
D Tallo, WB Malarkey |
American Journal of Obstetrics and Gynecology | 1985 |
Evaluation of hypothalamic dopaminergic function by neuropharmacologic means in aged women
D Cocchi, C Castoldi, S Locatelli, A Novelli, AM Colombo, A Tammaro, EE Mller |
Journal of Neural Transmission | 1985 |
Effect of L-dopa with and without inhibition of extra cerebral dopa decarboxylase on gastric acid secretion and gastrin release in man
R Caldara, C Barbieri, V Piepoli, M Borzio, E Masci |
Gut | 1985 |
Contemporary Endocrinology
SH Ingbar |
1985 | |
Neuroendocrine Perspectives
SR Ojeda, SS (White), HF Urbanski, LI Aguado |
Neuroendocrine Perspectives | 1984 |
Prolactin Secretion: a Multidisciplinary Approach
ME Molitch, S Reichlin |
Prolactin Secretion: a Multidisciplinary Approach | 1984 |
Mechanisms involved in the prolactin-releasing effect of benserazide
EA Parati, A Penalva, GP Bondiolotti, M Parenti, V Locatelli, GB Picotti, D Cocchi, EE Müller |
European Journal of Pharmacology | 1984 |
Psychoneuroendocrine Dysfunction
NS Shah, AG Donald |
1984 | |
Development of pituitary adenoma in women with hyperprolactinaemia: clinical, endocrine, and radiological characteristics
AE Pontiroli, L Falsetti |
BMJ : British Medical Journal | 1984 |
Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in man
JI Nurnberger, S Simmons-Alling, L Kessler, S Jimerson, J Schreiber, E Hollander, CA Tamminga, NS Nadi, DS Goldstein, ES Gershon |
Psychopharmacology | 1984 |
Peptides, Hormones, and Behavior
CB Nemeroff, AJ Dunn |
1984 | |
RECIPROCAL PATTERN OF THE TSH AND PRL RESPONSES TO DOPAMINE RECEPTOR BLOCKADE IN WOMEN WITH PHYSIOLOGICAL OR PATHOLOGICAL HYPERPROLACTINAEMIA
F Massara, F Camanni, M Martra, GC Dolfin, EE Müller, GM Molinatti |
Clinical Endocrinology | 1983 |
THE INTERRELATIONSHIPS BETWEEN PROLACTIN AND THYROTROPHIN SECRETION FOLLOWING DOPAMINERGIC BLOCKAGE IN PATIENTS WITH MILD HYPERPROLACTINAEMIA WITHOUT ANY DEMONSTRABLE PITUITARY TUMOUR
JM Spitz, M Haas, S Trestian, E Zylber-Haran, S Shilo |
Clinical Endocrinology | 1983 |
Investigation of hypothalamic-pituitary disease
RP Lamberton, IM Jackson |
Clinics in Endocrinology and Metabolism | 1983 |
TSH neuroregulation and alterations in disease states
JR Peters, SM Foord, C Dieguez, MF Scanlon |
Clinics in Endocrinology and Metabolism | 1983 |
The role of vasoactive intestinal polypeptide (VIP) as a hypothalamic neurohormone
S Nicosia, D Oliva, G Giannattasio, A Spada |
Journal of Endocrinological Investigation | 1983 |
Nomifensine, TRH and insulin-induced hypoglycemia tests in the diagnosis of prolactinomas
F Iannotta, P Fachinetti, A Fachinetti, G Pinotti, L Usellini |
Journal of Endocrinological Investigation | 1983 |
Neuroendocrinology of Aging
J Meites |
1983 | |
Prolactin-Lowering and -Releasing Drugs Mechanisms of Action and Therapeutic Applications:
EE Müller, V Locatelli, S Cella, A Peñalva, A Novelli, D Cocchi |
Drugs | 1983 |
PROLACTIN STIMULATION BY INTRAVENOUS LABETALOL IS MEDIATED INSIDE THE CENTRAL NERVOUS SYSTEM
C Barbieri, MT Larovere, G Mariotti, C Ferrari, R Caldara |
Clinical Endocrinology | 1982 |
PULSATILE GONADOTROPHIN SECRETION IN HYPERPROLACTINAEMIC AMENORRHOEA AND THE RESPONSE TO BROMOCRIPTINE THERAPY
PJ Moult, LH Rees, GM Besser |
Clinical Endocrinology | 1982 |
Effects of L-dopa on plasma levels of parathyroid hormone in calves
J Blum, D Schams, W Born, MD Prada |
Journal of Endocrinological Investigation | 1982 |
Long term bromocriptine therapy in Cushing’s disease
LP Kapcala, IM Jackson |
Journal of Endocrinological Investigation | 1982 |
Nomifensine-induced pregnancy in a hyperprolactinemic woman
AR Genazzani, VD Leo, F Camanni, EE Müller |
Journal of Endocrinological Investigation | 1982 |
Impaired prolactin responsiveness to dopamine antagonists in acromegaly
F Camanni, F Massara, M Santià, GM Molinatti, EE Müller |
Metabolism | 1982 |
Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery
A Barbarino, LD Marinis, C Anile, E Menini, G Merlini, G Maira |
Metabolism | 1982 |
Damage to Hypothalamic Dopaminergic Neurons Is Associated with Development of Prolactin-Secreting Pituitary Tumors
DK Sarkar, PE Gottschall, J Meites |
Science | 1982 |
ALTERED DOPAMINERGIC REGULATION OF THYROTROPHIN RELEASE IN PATIENTS WITH PROLACTINOMAS: COMPARISON WITH OTHER TESTS OF HYPOTHALAMIC-PITUITARY FUNCTION
MF Scanlon, MD Rodriguez-Arnao, AM McGREGOR, D Weightman, M Lewis, DB Cook, A Gomez-Pan, R Hall |
Clinical Endocrinology | 1981 |
Abnormal prolactin responsivity to dopaminergic suppression in hyperprolactinemic patients
S Bansal, LA Lee, PD Woolf |
The American Journal of Medicine | 1981 |
A possible role for endogenous opioids in the control of prolactin and luteinizing-hormone secretion in the human
JD Veldhuis, TJ Worgul, R Monsaert, JM Hammond |
Journal of Endocrinological Investigation | 1981 |
Effects of increased central dopaminergic tonus on gonadotropin secretion
P Travaglini, C Montanari, M Ballabio, R Elli, RC Scaperrotta, G Faglia |
Journal of Endocrinological Investigation | 1981 |
Dopamine-mimetic and antagonist drugs: Diagnostic and therapeutic applications in endocrine disorders
EE Müller, F Camanni, AR Genazzani, F Casanueva, D Cocchi, V Locatelli, F Massara, P Mantegazza |
Life Sciences | 1981 |
Validity of hypothalamic-pituitary testing in hyperprolactinemia: Prolactin responses to insulin hypoglycemia and arginine
DF Archer, JH Harger, EE Moore, LJ Hough |
American Journal of Obstetrics and Gynecology | 1981 |
Tests of Prolactin Secretion in the Diagnosis of Hyperprolactinemic States: Nomifensine and Domperidone**Supported by grants from Project “Biology and Reproduction,” Consiglio Nationale delle Ricerche (C.N.R.), Rome (to A. R. G. and E. E. Müller)
F Massara, AR Genazzani, F Camanni, VD Leo, GM Molinatti, EE Müller |
Fertility and Sterility | 1981 |
Growth hormone and prolactin stimulation by Madopar in Parkinson's disease
A Martinez-Campos, P Giovannini, E Parati, A Novelli, T Caraceni, E Muller |
Journal of neurology, neurosurgery, and psychiatry | 1981 |
Neuroendocrine Regulation and Altered Behaviour
PD Hrdina, RL Singhal |
1981 | |
EFFECT OF DOPAMINE INFUSION ON SERUM PROLACTIN CONCENTRATION IN NORMAL AND HYPERPROLACTINAEMIC SUBJECTS
E Reschini, C Ferrari, M Peracchi, R Fadini, M Meschia, PG Crosignani |
Clinical Endocrinology | 1980 |
Diminished prolactin reserve in acromegaly
IM Spitz, D Barzilai, R Luboshitzky |
Metabolism | 1980 |
Prolactin-secreting pituitary adenomas: Serum and tissue prolactin levels with ultrastructural correlation
DF Archer, H Salazar, JC Maroon, LJ Hough |
American Journal of Obstetrics and Gynecology | 1980 |
The Pituitary Adenoma
KD Post, IM Jackson, S Reichlin |
1980 | |
Trends in the management of prolactinomas.
|
British medical journal | 1980 |
Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin
MF Scanlon, M Pourmand, AM McGregor, MD Rodriguez-Arnao, K Hall, A Gomez-Pan, R Hall |
Journal of Endocrinological Investigation | 1979 |
Relationship of butaperazine blood levels to plasma prolactin in chronic schizophrenic patients
RC Smith, CA Tamminga, JW Crayton, H Dekirmenjian, JM Davis |
Psychopharmacology | 1979 |
Clinical Neuroendocrinology
CR Edwards |
Clinical Neuroendocrinology | 1977 |